Treatment of MS with Copaxone and Albuterol (AMS01)

A randomized, double-masked, 2-arm pilot study of Copaxone and albuterol versus Copaxone and placebo for the treatment of multiple sclerosis. Twenty-four patients with MS who meet the inclusion/exclusion criteria will be enrolled per arm. Each patient will be randomized to receive either 20 mg SQ of Copaxone plus an oral dose of placebo daily or 20 mg SQ of Copaxone plus an oral dose of albuterol daily. Patients will be followed for two years.

本研究为一项对比醋酸格拉替雷（Copaxone）联合沙丁胺醇（albuterol）与醋酸格拉替雷（Copaxone）联合安慰剂治疗多发性硬化症（multiple sclerosis，MS）的随机、双盲、双臂先导临床试验。每组将纳入24例符合入排标准的多发性硬化症（MS）患者。所有患者将被随机分配至两个组别之一：每日皮下注射（SQ）20mg醋酸格拉替雷联合口服安慰剂，或每日皮下注射（SQ）20mg醋酸格拉替雷联合口服沙丁胺醇。所有患者将接受为期两年的随访。